NPPA notified regarding the computation of the retail price of Empagliflozin 12.5 mg + Metformin Hydrochloride IP 1000 mg (as extended release) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) and M/s Cadila Pharmaceuticals Ltd. (Marketer)

Feb 28, 2025 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific Complianceclass="MsoNormal" style="text-align: justify;">The National Pharmaceutical Pricing Authority (NPPA) on February 27, 2025, was notified regarding the computation of the retail price of Empagliflozin 12.5 mg + Metformin Hydrochloride IP 1000 mg (as extended release) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) and M/s Cadila Pharmaceuticals Ltd. (Marketer).

It states that the price of each Film Coated Bilayered Tablet containing: Empagliflozin 12.5 mg + Metformin Hydrochloride IP 1000 mg (as extended release) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) and M/s Cadila Pharmaceuticals Ltd. (Marketer) has been revised to Rs. 19.01/-.


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT